This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary TSLP Therapeutic Antibody Development
Background of TSLP
TSLP plays a vital role in regulating immune responses in conditions like atopic dermatitis and other immune-allergic diseases. Therapeutic antibodies targeting TSLP represent a potential strategy for treating these diseased companion animals. BioVenic offers comprehensive veterinary TSLP therapeutic antibody development services, covering the entire process from antibody preparation using novel technologies to purification, and characterization, committed to facilitating the development of high-quality veterinary therapeutic antibodies.
Background of TSLP
| Full Name | Thymic stromal lymphopoietin |
|---|---|
| Aliases | / |
| Target Profile | TSLP is a multifunctional cytokine that influences a variety of cell lineages including dendritic cells, T cells, B cells, neutrophils, mast cells, eosinophils, and innate lymphoid cells, affecting their maturation, survival, and recruitment. TSLP primarily modulates immune responses, particularly T helper 2 (Th2) cell responses, which are crucial in the pathogenesis of allergic diseases and autoimmune disorders. |
MoA of TSLP
TSLP functions through its unique receptor complex composed of TSLPR and IL-7Rα. This receptor complex is widely expressed on various cells, including dendritic cells, mast cells, macrophages, basophils, T cells, as well as epithelial cells and neurons. After binding to its receptor complex, TSLP triggers the activation of JAK1 and JAK2, which then activates the signal transducer and activator of transcription 5A and 5B (STAT5A and STAT5B). These activated signaling molecules further promote the production of type 2 cytokines such as IL-4, IL-5, IL-9, and IL-13, contributing to its pro-inflammatory effects.
Fig.1 Schematic diagram of TSLP-induced signaling mechanisms. 1
Application in Veterinary Therapeutics
TSLP stimulates dendritic cells to induce the differentiation of naive T cells into inflammatory Th2 cells, leading to the production of inflammatory cytokines like IL-13, IL-4, and TNF-α. Elevated expression of TSLP in the canine skin with atopic dermatitis underscores its involvement in this disease. Monoclonal antibodies targeting TSLP have been extensively researched for various allergic inflammatory diseases, including severe asthma, atopic dermatitis, food allergies, allergic rhinitis, and Netherton syndrome. TSLP therapeutic antibodies hold potential in treating companion animal diseases by specifically binding to TSLP and blocking its interaction with its receptor, effectively suppressing related immunopathological responses.
Veterinary TSLP Therapeutic Antibody Development Services
Given the role of aberrant TSLP expression in allergic diseases and inflammatory responses in companion animals, targeting TSLP for therapeutic intervention presents a viable option. BioVenic offers veterinary TSLP therapeutic antibody development services. Our services encompass the entire process from target identification, antibody design, and expression, to purification and functional validation, ensuring high-affinity antibodies that effectively recognize and bind TSLP. We also offer species-specific antibody development services, including antibody caninization/felinization and fully canine/feline antibody development, to reduce antibody immunogenicity.
Please click the link below for more information about our veterinary TSLP therapeutic antibody development services.
Why Choose Us?
Our range of services extends from gene synthesis to animal immunization, antibody preparation, purification, and characterization, offering a one-stop solution for convenient and efficient therapeutic antibody development.
Our team tailors species-specific antibody development solutions to meet the unique therapeutic needs of different companion animals, maintaining low immunogenicity while ensuring high efficacy.
We emphasize strict quality control during the development process, to ensure that the antibody samples we assist in developing maintain high purity and stability, closely aligning with theoretical conditions in research.
TSLP plays a key role in immune regulation and allergic and autoimmune diseases in companion animals, making antibodies targeting TSLP a potent treatment option for such conditions. BioVenic provides one-stop veterinary TSLP therapeutic antibody development services, supporting the development of high-quality antibodies for a broader range of diseases. For more information or to discuss your specific needs, please feel free to contact us.
References
- Ebina-Shibuya, Risa, and Warren J. Leonard. "Role of thymic stromal lymphopoietin in allergy and beyond." Nature Reviews Immunology 23.1 (2023): 24-37.
- Klukowska‐Rötzler, Jolanta, et al. "Expression of thymic stromal lymphopoietin in canine atopic dermatitis." Veterinary dermatology 24.1 (2013): 54-e14.